Emicizumab prophylaxis in patients who have hemophilia a without inhibitors

New England Journal of Medicine

Volumn 379, Issue 9, 2018, Pages 811-822

  Mahlangu, J ^a   Oldenburg, J ^b   Paz Priel, I ^c   Negrier, C ^d   Niggli, M ^e   Mancuso, M E ^f   Schmitt, C ^e   Jimenez Yuste V ^g   Kempton, C ^h   Dhalluin, C ^e   Callaghan, M U ⁱ   Bujan, W ^j   Shima, M ^k   Adamkewicz, J I ^c   Asikanius, E ^e   Levy, G G ^c   Kruse Jarres, R ^l  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c GENENTECH INC   (United States)

^d LOUIS PRADEL HOSPITAL   (France)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^j Inst Costarricense Invest Clinicas   (Costa Rica)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l Washington Center for Bleeding Disorders at Bloodworks Northwest   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; EMICIZUMAB; BISPECIFIC ANTIBODY; BLOOD CLOTTING INHIBITOR; MONOCLONAL ANTIBODY;

ALOPECIA; ARTHRALGIA; ARTICLE; BLEEDING; BODY WEIGHT; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEMOPHILIA A; HUMAN; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; LETHARGY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NIGHTMARE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; MALE; MIDDLE AGED; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COAGULATION FACTOR INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; QUALITY OF LIFE; YOUNG ADULT;

EID: 85052877162     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1803550     Document Type: Article

References (31)

1. Mannucci PM, Tuddenham EGD. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27: 179-84.
3. Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem 2002; 35: 141-8.
4. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329-35.
5. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11: Suppl 1: 84-98.
6. Eton DT, Elraiyah TA, Yost KJ, et al. A systematic review of patient-reported measures of burden of treatment in three chronic diseases. Patient Relat Outcome Meas 2013; 4: 7-20.
7. Mair FS, May CR. Thinking about the burden of treatment. BMJ 2014; 349: g6680.
8. Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol 2015; 169: 777-86.
9. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570-4.
10. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8(2): e57479.
11. Hemlibra (emicizumab) summary of product characteristics. Basil, Switzerland: F. Hoffmann-La Roche, 2018 (http://www .ema .europa .eu/ docs/ en-GB/ document- library/ EPAR-Product- Information/ human/ 004406/ WC500244743 .pdf).
12. Hemlibra (emicizumab) prescribing information. South San Francisco, CA: Genentech, 2017 (https://www .gene .com/ download/ pdf/ hemlibra-prescribing .pdf).
13. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-18.
14. Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors. Presented at the annual meeting of the American Society of Hematology, Atlanta, December 9-12, 2017. abstract.
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis 1997; 48: 231-4.
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.
17. Yoneyama K, Schmitt C, Kotani N, et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet 2017 December 6 (Epub ahead of print).
18. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-53.
19. Kruse-Jarres R, Oldenburg J, Santagostino E, et al. Bleeding events and safety outcomes in persons with haemophilia A (PwHA) without inhibitors: non-interventional study (NIS) from a real-world setting. Presented at the 11th annual congress of the European Association for Haemophilia and Allied Disorders, Madrid, February 7-9, 2018. abstract.
20. von Mackensen S, Gringeri A, Ravera S, et al. Validation of the Haemophilia- Specific Quality of Life Questionnaire for adult patients with haemophilia (Haem-AQoL). Haematologica 2005; 90: Suppl 2: 115-6.
21. Wyrwich KW, Krishnan S, Poon JL, et al. Interpreting important health-related quality of life change using the Haem-AQoL. Haemophilia 2015; 21: 578-84.
22. Miller CH, Rice AS, Boylan B, et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost 2013; 11: 1300-9.
23. Adamkewicz JI, Schmitt C, Asikanius E, et al. Factor VIII inhibitor testing using a validated chromogenic Bethesda assay in HAVEN 1 (BH29884), a phase 3 trial of emicizumab in persons with hemophilia A with inhibitors. Res Pract Thromb Haemost 2017; 1: Suppl 1: 724.
24. Mancuso ME, Callaghan MU, Kruse- Jarres R, et al. Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study. Presented at the annual meeting of the American Society of Hematology, Atlanta, December 9-12, 2017. abstract.
25. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117: 1348-57.
26. Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost 2018; 16: 1078-88.
27. Adamkewicz JI, Muto A, Soeda T, Suzuki S, Kitazawa T. In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro-coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC. Haemophilia 2017; 23: Suppl 2: 26.
28. Pipe S, Jimenez-Yuste V, Shapiro A, et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors - results from the phase 3 HAVEN 4 study. Presented at the 2018 world congress of the World Federation of Hemophilia, Glasgow, United Kingdom, May 20-24, 2018. abstract.
29. Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377: 2519-30.
30. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017; 377: 2215-27.
31. Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018; 131: 1022-31.